Гемоглобинопатии и талассемические синдромы. / Под ред. Румянцева А.Г., Токарева Ю.Н., Сметаниной Н.С. Практическая медицина, 2015 г., 448 С.
Денисеня Г. Хелаторная терапия: новые возможности лечения редких заболеваний. Медицинский вестник, 2011. 27.
Сметанина Н.С., Токарев Ю.Н. Хелаторная терапия при вторичной (посттрансфузионной) перегрузке железом. Гематология и трансфузиология, 1999. 5: 44-46.
Анемии у детей. Под ред. Румянцева А.Г., Токарева Ю.Н., М.: Макс- Пресс, 2000, 216 с.
Сметанина Н.С. Современные возможности хелаторной терапии. Российский журнал детской гематологии и онкологии, 2014, 1: 51-59.
Porter JB. Practical management of iron overload. Br J Haematol. 2001. 115: 239-252.
Modell B. Total management of thalassemia major. Archives of Diseases in Childhood. 1977. 52: 485-500.
Thalassemia International Federation (TIF) Guidelines 2000.
Porter JB. Concepts and goals in the management of transfusional iron overload. Am J Hematol. 2007. 82(S12): 1136-9.
Гаттерманн Н. Железо: какое количество считать избыточным у больных МДС? Борьба с перегрузкой железом при МДС. IRON JOURNAL CLUB. 2008, 2, 1: 2.
Ohen A, Masera G, Zoumbos N et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with defera-sirox (Exjade®, ICL670). Blood (ASH Annual Meeting Abstracts). 2005. 106: Abstract 822.
Angelucci E, Brittenham GM, McLaren CE et al. Hepatic iron concentra- tion and total body iron stores in thalassemia major. N Engl J Med. 2000. 343(5): 327-31.
Angelucci E, Baronciani D, Lucarelli G et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol. 1995. 89(4): 757-61.
Wood JC, Enriquez C, Ghugre N et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005. 106(4): 1460-5.
Hankins JS, McCarville MB, Loeffler RB et al. R2* magnetic resonance imaging of the liver in patients with ironoverload. Blood. 2009. 113: 4853-5.
Kirk P, He T, Anderson LJ et al. International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging. 2010. 32(2): 315-9.
Porter JB, Heuhns E. The toxic effects of desferoxamine. Bailliere's Clin. Haematol. 1989. 2: 459-474.
Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with desferrioxamine therapy. Blood. 1996. 88: 705-714.
Olivieri NF, Nathan DG, Macmillan JH et al. Survival in medically treated patients with homozygous beta-thalassemia. N. Engl. J. Med. 1994. 331: 574-578.
Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000. 95: 1229-1236.
Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 2004 104: 263-269.
Piga A, Luzzatto L, Capalbo P et al. High dose desferrioxamine as a cause of growth failure in thalassaemic patients. Eur. J. Haematol. 1988. 40: 380-381.
Olivieri NF, Koren G, Harris J et al. Growth failure and bony changes induced by deferoxamine. Am. J. Pediatr. Hematol. Oncol. 1992. 14: 48-56.
Olivieri NF, Koren G, Hermann C et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet. 1990. 336: 1275-1279.
Cohen AR, Galanello R, Piga A et al. Safety profile of the oral iron chelator deferiprone: a multicen-tre study. Br. J. Haematol. 2000. 108: 305-312.
Tanner MA, Galanello R, Dessi C et al. A randomised, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalas-saemia major using cardiovascular magnetic resonance. Circulation. 2007. 115. 14: 1876-1884.
Красильникова М.В., Лохматова М.Е., Сметанина Н.С. Комбинированная хелаторная терапия трансфузионно-зависимой бета-талассемии у детей и подростков. Вопросы гематологии/онкологии и иммунологии в педиатрии. 2014. 13, 2: 42-45.
Haemoglobinopathy and thalassemic syndromes. / Ed. by Rumyantsev A.G., Tokarev Y.N., Smetanina N.S. Prakticheskaya Meditsina, 2015, 448 p.
Denisenya G. Chelation therapy: new treatment options for rare diseases. // Meditsinskiy Vestnik, 2011; Vol 27.
Smetanina N.S., Tokarev Y.N. Chelation therapy for secondary (post-transfusion) iron overload. Gematologiya i Transfuziologiya, 1999. 5: 44-46.
Anemia in children. Ed. by Rumyantsev A.G., Tokarev Y.N., M.: Maks-Press, 2000, 216 p.
Smetanina N.S. Current options for chelation therapy. Rossiyskiy Zhurnal Detskoy Gematologii i Onkologii, 2014, 1: 51-59.
Gattermann N. Iron: which amount should be considered excessive in patients with MDS? Combating iron overload in MDS. IRON JOURNAL CLUB. 2008, 2, 1: 2.
Krasil'nikova M.V., Lokhmatova M.E., Smetanina N.S. Combination chelation treatment of transfusion-dependent b-talassemia in children and adolescents. Voprosy Gematol./Onkol. i Immunol. v Pediatrii. 2014. 13, 2: 42-45.